Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas

Clinical Cancer Research

Volumn 3, Issue 4, 1997, Pages 593-600

  Makris, Andreas ^a   Powles, T J ^a   Dowsett, M ^b   Osborne, C K ^d   Trott, P A ^b   Fernando, I N ^a   Ashley, S E ^a   Ormerod, M G ^c   Titley, J C ^c   Gregory, R K ^a   Allred, D C ^d  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; MITOMYCIN C; MITOXANTRONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; MITOMYCIN; MITOXANTRONE; NEOPLASM STAGING; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; S PHASE; TAMOXIFEN;

EID: 0030916465     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Scholl, S. M., Fourquet, A., Asselain, B., Pierga, J. Y., Vilcoq, J. R., Durand, J. C., Dorval, T., Palangie, T., Jouve, M., Beuzeboc, P., Garcio-Giralt, E., Salmon, R. J., de la Rochefordiere, A., Campana, F., and Pouillart, P. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur. J. Cancer, 30A: 645-652, 1994.
2. Jacquillat, C., Weil, M., Baillet, F., Borel, C., Auclerc, G., de Maublanc, M. A., Housett, M., Forget, G., Thill, L., Soubranne, C., and Khayat, D. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer (Phila.), 66: 119-129, 1990.
3. Powles, T. J., Hickish, T. F., Makris, A., Ashley, S. E., O'Brien, M. E. R., Tidy, V. A., Casey, S., Nash, A. G., Sacks, N., Cosgrove, D., MacVicar, D., Fernando, I., and Ford, H. T. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J. Clin. Oncol., 13: 547-552, 1995.
4. Bonadonna, G., Valagusa, P., Brambilla, C., and Ferrari, L. Preoperative chemotherapy in operable breast cancer. Lancet, 341: 1485, 1993.
5. Bonadonna, G., Veronesi, U., Brambilla, C., Ferrari, L., Luini, A., Greco, M., Bartoli, C. Coopmans de Yoldi, G., Zucali, R., Rilke, F., Andreola, S., Silvestrini, R., Di Fronzo, G., and Valagussa, P. Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimeters or more. J. Natl. Cancer Inst., 82: 1539-1545, 1990.
6. Hortobagyi, G. N., Ames, F. C., Buzdar, A. U., Kau, S. W., McNeese, M. D., Paulus, D., Hug, V., Holmes, F. A., Romsdahl, M. M., Fraschini, G., McBride, C. M., Martin, R. G., and Montague, E. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer (Phila.), 62: 2507-2516, 1988.
7. Kline, T. S., Joshi, L. P., and Neal, H. S. Fine-needle aspiration of the breast; diagnoses and pitfalls (a review of 3545 cases). Cancer (Phila.), 44: 1458-1464, 1979.
8. Makris, A., Powles, T. J., Dowsett, M., Allred, D. C., Trott, P. A., Fernando, I. N., Ormerod, M. G., and Ashley, S. Cytological assessment of prognosis and response to primary medical therapy in primary breast carcinoma. Br. J. Cancer, 72: 25, 1995.
9. Anderson, E. D. C., Forrest, A. P. M., Levack, P. A., Chetty, U., and Hawkins, R. A. Response to endocrine manipulation and oestrogen receptor concentration in large operable breast cancer. Br. J. Cancer, 60: 223, 1989.
10. McGuire, W. L. The usefulness of steroid receptors in the management of primary and advanced breast cancer. In: H. T. Moudison and T. Palshof (eds.), Breast cancer: Experimental and Clinical Aspects, pp. 39-43. New York: Pergammon Press, 1980.
11. O'Reilly, S. M., Camplejohn, R. S., Rubens, R. D., and Richards, M. A. DNA flow cytometry and response to preoperative chemotherapy from primary breast cancer. Eur. J. Cancer. 28: 681-683, 1992.
12. Gottardi, O., Scanzi, F., Zurrida, S., Bono, A., Majno, M., Colombo, P., Ferrari, M., Gambacocta, M., and Rossi, N. Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer. Breast, 208: 33-36, 1993.
13. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Earl Ruley, H., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
14. Allred, D. C., Clark, G. M., Fuqua, S. A. W., Elledge, R. M., Hilsenbeck, S. G., Ravdin, P. M., Yee, D., Chamness, G. C., and Osborne, C. K. Overexpression of p53 in node-positive breast cancer. Breast Cancer Res. Treat., 27: 131, 1993.
15. Hsu, B., Marin, M. C., Brisbay, S., McConnell, K., and McDonnell, T. J. Expression of bcl-2 gene confers multidrug resistance to chemotherapy-induced cell death. Cancer Bull., 46: 125-129, 1994.
16. Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Castiglione, M., Collins, J., Lindtner, J., and Senn, H. J. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol., 10: 1049-1056, 1992.
17. Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., and Henderson, I. C. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1994.
18. Houston, S. J., Barnes, D. M., Smith, P., Miles, D. W., Richards, M. A., and Rubens, R. D. Increased expression of c-erbB-2 and decreased response to endocrine treatment of breast cancer. Br. J. Cancer, 71: 9, 1995.
19. Wright, C., Nicholson, S., Angus, B., Sainsbury, J. R. C., Farndon, J., Cairns, J., and Harris, A. L. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer, 65: 118-121, 1992.
20. Montes, A., Powles, T. J., O'Brien, M. E. R., Ashley, S. E., Luckitt, J., and Treleavan, J. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur. J. Cancer, 29A: 1854-1857, 1993.
21. Hayward, J. L., Carbone, P. P., Heuson, J. C., Kumaoka, S., Segaloff, A., and Rubens, R. D. Assessment of response to therapy in advanced breast cancer. Br. J. Cancer, 35: 292-298, 1977.
22. Vinnicombe, S. J., MacVicar, D., Guy, R. L., Sloane, J. K., Knee, G., Powles, T. J., and Husband, J. E. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy with pathological correlation. Radiology, 198: 333-340, 1996.
23. Walker, K. J., Bouzubar, N., Robertson, J., Ellis, I. O., Elston, C. W., Blarney, R. W., Wilson, D. W., Griffiths, K., and Nicholson, R. I. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res., 48: 6517-6522, 1988.
24. Allred, D. C., Bustamante, M. A., Daniel, C. O., Gaskill, H. V., and Cruz, A. B. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Arch. Surg., 125: 107-113, 1990.
25. Ormerod, M. G. Flow Cytometry: A Practical Approach. Oxford, United Kingdom: Oxford University Press, 1994.
26. Bozzetti, C., Nizzoli, R., Naldi, N., Manotti, L., Savoldi, L., Camisa, R., Guazzi, A., and Cocconi, G. Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma. Breast Cancer Res. Treat., 32: 221-228, 1994.
27. Powles, T. J., Jones, A. L., Judson, I. R., Hardy, J. R., and Ashley, S. E. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3 M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br. J. Cancer, 64: 406-410, 1991.
28. Early Breast Cancer Triallists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 1-15, 1992.
29. Powles, T. J., and Smith, I. E. Adjuvant treatment in breast cancer. Lancet, 339: 423, 1992.
30. Norton, L., and Simon, R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep., 61: 1307-1317, 1977.
31. Horwitz, K. B., McGuire, W. L., Pearson, O. H., and Segaloff, A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science (Washington DC), 189: 726-727, 1975.
32. Muss, H. B. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res. Treat., 21: 15-26, 1992.
33. Ravdin, P. M., Green, S., Melink Dorr, T., McGuire, W. L., Fabian, G., Pugh, R. P., Carter, R. D., Rivkin, S. E., Borst, J. R., Belt, R. J., Metch, B., and Osborne, C. K. Prognostic significance of progesterone receptor levels in estrogen-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol., 10: 1284-1291, 1992.
34. Low, S. C., Dixon, A. R., Bell, J., Ellis, I. O., Robert son, J. F. R., and Blarney, R. W. Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment. Br. J. Surg, 79: 1314-1316, 1992.
35. Robertson, J. F. R., Bates, K., Pearson, O., Blarney, R. W., and Nicholson, R. I. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br. J. Cancer, 65: 727-730, 1992.
36. Gaskell, D. J., Hawkins, R. A., de Carteret, S., Chetty, U., Sangster, K., and Forrest, A. P. M. Indications for primary tamoxifen therapy in elderly women with breast cancer. Br. J. Surg, 79: 1317-1320, 1992.
37. Davies, N., Moir, G., Carpenter, R., Cuthbert, A., Herbert, A., Royle, G. T., and Taylor, I. ERICA predicts response to tamoxifen in elderly women with breast cancer. Ann. R. Coll. Surg. England, 73: 361-363, 1991.
38. Lippman, M. E., Allegra, J. C., Thompson, E. B., Simon, R., Barlock, A., Green, L., Huff, K. K., Do, H. M. T., Aitken, S. C., and Warren, R. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med., 295: 1223-1228, 1978.
39. Scottish Cancer Trials Breast Group and ICRF Breast Unit, G. H., London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish Trial. Lancet, 341: 1293-1298, 1993.
40. Remvikos, Y., Beuzeboc, A., Zajdela, N., Voillemot, N., Magdelenat, H., and Pouillart, P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J. Natl. Cancer Inst., 81: 1383-1387, 1989.
41. Hietanen, P., Blomqvist, C., Wasenius, V. M., Niskanen, E., Franssila, K., and Nordling, S. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br. J. Cancer, 71: 1029-1032, 1995.
42. Brifford, M., Spyratos, F., Hacene, K., Tubiana-Hulin, M., Pallud, C., Gilles, F., and Rouesse, J. Evaluation of breast carcinoma chemosensitivity by flow cytometric DNA analysis and computer assisted image analysis. Cytometry, 13: 250-258, 1992.
43. Bonetti, A., Sperotto, L., Turazza, M., Cetto, G. L., Nortilli, R., Bonetti, F., Piubello, Q., and Molini, A. Tumor proliferative activity and response to first-line chemotherapy in advanced breast cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 13: A112, 1994.
44. Billgren, A., Rutqvist, L. E., Skoog, L., and Wilking, N. Changes of proliferating fraction during neoadjuvant chemotherapy of primary breast cancer as a predictor of objective response. Breast Cancer Res. Treat., 32: 63, 1994.
45. Paradiso, A., Tommasi, S., Mangia, A., Lorusso, V., Simone, G., and De Lena, M. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Res., 50: 2958-2962, 1990.
46. Allred, D. C., Clark, G. M., Elledge, R., Fuqua, A. W., Brown, R. W., Chamnes, G. C., Osborne, C. K., and McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 55: 200-206, 1993.
47. Elledge, R. M., and Allred, D. C. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res. Treat., 32: 39-47, 1994.
48. McIlwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for adiosensitivity. Cancer Res., 54: 3718-3722, 1994.
49. Koechli, O. R., Schaer, G. N., Siefert, B., Hormung, R., Haller, U., Eppenberger, U., and Muller, H. Mutant p53 protein associated with chemosensitivity in breast cancer patients. Lancet, 344: 1647-1648, 1994.
50. Lowe, S. W., Earl Ruley, H., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
51. Mathieu, M., Koscielny, S., Le Bihan, M., Spielmann, M., and Arriagada, R. p53 protein overexpression and chemosensitivity in breast cancer. Lancet, 345: 1182, 1995.
52. Dive, C., Evans, C. A., and Whetton, A. D. Induction of apoptosis: new targets for cancer chemotherapy. Semin. Cancer Biol., 3: 417-427, 1992.
53. Walton, M. I., Whysong, D., O'Connor, P. M., Hockenbery, D., Korsmeyer, S. J., and Kohn, K. W. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res., 53: 1853-1861, 1993.
54. Ohmori, T., Podack, E. R., and Nishio, K. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun. 192: 30-36, 1993.
55. Elledge, R., Green, S., Howes, L., Berardo, M., Allred, D. C., Clark, G., Ciocca, D., Osborne, C. K., Ravdin, P., O'Sullivan, J., and Lagone, G. bcl-2, p53, and response to tamoxifen in ER-positive metastatic breast cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 15: 123, 1996.
56. Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., Eudey, L., and McGuire, W. L. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol., 10: 599-605, 992.
57. Leitzel, K., Teramoto, Y., Konrad, K., Chinchilli, V. M., Volas, G., Grossberg, H., Harvey, H., Demers, L., and Lipton, A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol., 13: 1129-1135, 1995.
58. Borg, A., Baldetorp, B., Fernoe, M., Killander, D., Olsson, H., Ryden, S., and Sigurdsson, H. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett., 81: 137-144, 1994.
59. Kiang, D. T., Frenning, D. H., Goldman, A. I., Ascensao, V. F., and Kennedy, B. J. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N. Engl. J. Med., 299: 1330-1334, 1978.